Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
about
New molecular targets in mantle cell lymphomaNovel agents in mantle cell lymphomaMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSmall molecule deubiquitinase inhibitors promote macrophage anti-infective capacityDeubiquitinating enzymes as promising drug targets for infectious diseases.Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinomaOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Molecular targeted approaches in mantle cell lymphoma.Screening of DUB activity and specificity by MALDI-TOF mass spectrometryT cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10.Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.A small molecule deubiquitinase inhibitor increases localization of inducible nitric oxide synthase to the macrophage phagosome and enhances bacterial killingOver-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideBortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.From bortezomib to other inhibitors of the proteasome and beyond.Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated AutophagyThe preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries.Novel therapies for aggressive B-cell lymphomaMetal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
P2860
Q26821766-3FB4324D-D00B-4C9C-BE53-EA0057C79413Q27011763-A14797F0-5902-4E41-BCB6-5E81D5A26CF5Q28075606-DF165BC2-303A-4056-AE00-81FF606BAEABQ28541638-89D40634-8CBE-48FB-84CE-E49858EBA19AQ33836097-E23E1D8D-0B73-4CCB-939F-B6EE298C7DEDQ33989933-F57C0C2C-71FB-4BDB-AACB-5944CCCEF229Q34788381-76802C2E-E094-40D5-B738-992168612764Q35127368-041BA8A4-1746-4313-A9D1-EEF250852441Q35232335-0335E6D8-FD60-4D14-AB56-868CA0DC2C8CQ35510049-4FDC8C19-7E28-4B1C-9FDD-A676BBCC3783Q35559055-6D4E1F7F-B2A0-42FA-A70D-AF834E72492CQ35598040-68037573-584D-4D31-B16F-DFE1E1E9349FQ35987083-55483985-3A60-4382-B0BF-4883F7A7BEF3Q35989980-D28EFD44-EE59-4332-ABFF-EBED62E6A7A8Q36825684-75C6D921-B0C2-41A4-9B88-F70D837577AAQ36852277-3B2B7A5A-B271-475A-9382-A49525DD91B2Q37073598-02D23D28-5ECC-4AC1-A836-7CB5BE721F78Q37697049-EA74813B-E755-4A61-9AD7-E0A02F4BFF54Q38693406-0AC239F9-06F4-4D71-AB4B-B5BFF53B3898Q38695071-7788CA31-4CC8-4479-964E-34B04EC4ABE6Q38734433-8714BF76-14B9-4A2C-8FC6-C737E41AD370Q39029195-0C614166-4E3F-4532-8C48-50E0D88385DFQ39257016-0446DEC0-B4DD-4A34-9090-A82A1672D9F0Q42011578-F7640FDD-D00C-4793-BF44-E260F3B09831Q47098444-8F08AAD4-9603-4209-9A79-3774E800255BQ50128397-3C50B256-7785-4BA4-A55A-08DE4E760410
P2860
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@ast
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@en
type
label
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@ast
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@en
prefLabel
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@ast
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@en
P2093
P2860
P1476
Degrasyn potentiates the antit ...... ivo: therapeutic implications.
@en
P2093
Archito T Tamayo
Changping Li
Lan V Pham
Richard J Ford
Waldemar Priebe
William Bornmann
P2860
P304
P356
10.1158/1535-7163.MCT-10-0238
P577
2010-07-06T00:00:00Z